Individualized Obesity Pharmacotherapy

NCT03374956 · Completed

Last updated 2026-05-28

This clinical trial tests different weight-loss medications tailored to individuals with obesity to see how much total body weight changes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 193 people

Who can join Ages 18–75 · all sexes

Timeline Started 2017-12 · est. completion 2022-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03374956 ↗

Description as written by the study sponsor.

The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.

Treatments tested

Phentermine-Topiramate also known as Qsymia Drug

Extended Release at dose of 7.5/46 mg oral daily
Liraglutide also known as Saxenda Drug

dose of 3 mg subcutaneous daily
Naltrexone/bupropion also known as Contrave Drug

Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
Phentermine also known as Adipex-P, Lomaira Drug

15-37.5 mg oral daily

Main thing measured	Change in Total Body Weight
Sponsor	Mayo Clinic
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03374956 ↗